Abbonarsi

Measuring the global response to antimicrobial resistance, 2020–21: a systematic governance analysis of 114 countries - 25/05/23

Doi : 10.1016/S1473-3099(22)00796-4 
Jay Patel a, b, , Anne Harant, PhD c, d, Genevie Fernandes, PhD a, Ambele Judith Mwamelo, MPH a, Wolfgang Hein, ProfPhD c, Denise Dekker, PhD e, Devi Sridhar, ProfPhD a
a Global Health Governance Programme, Usher Institute, University of Edinburgh, Edinburgh, UK 
b School of Dentistry, Faculty of Medicine and Health, University of Leeds, Leeds, UK 
c German Institute of Global and Area Studies, Hamburg, Germany 
d Faculty of Business, Economics and Social Sciences, University of Hamburg, Hamburg, Germany 
e Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany 

* Correspondence to: Mr Jay Patel, Global Health Governance Programme, Usher Institute, University of Edinburgh, Edinburgh EH8 9AG, UK Global Health Governance Programme Usher Institute University of Edinburgh Edinburgh EH8 9AG UK

Summary

Background

Understanding strategic commitments and policy responses to overcome antimicrobial resistance at the national, regional, and global levels is required to evaluate current progress and direct future planning. National action plans (NAPs) are the primary mechanism for guiding national strategy and action for antimicrobial resistance governance. Although several NAPs have been developed, no comprehensive content analysis of these plans exists. Using a governance framework, we aimed to assess all publicly available NAPs on antimicrobial resistance.

Methods

We systematically reviewed the contents of NAPs on antimicrobial resistance from 114 countries, applying a governance framework containing 18 domains and 54 indicators in three integral areas: policy design, implementation tools, and monitoring and evaluation. As well as manually searching NAPs and doing online and literature searches that were relevant to specific indicators from repository inception to June 1, 2022, several data sources were used to generate scores, including the Tripartite Antimicrobial Resistance Country Self-Assessment Survey, the Global Antimicrobial Resistance and Use Surveillance System, the Global Antimicrobial Resistance Research and Development Hub, and various WHO datasets. NAPs were included if the country had also submitted the NAP to the Tripartite Antimicrobial Resistance Country Self-Assessment Survey 2020–21, if the NAP was retrievable through a publicly accessible database or website, and if the NAP was either published in English or eligible for machine translation. Three researchers independently reviewed each NAP and were initially blinded to the evaluations of other researchers. They generated a score using a quantification system for each of 54 indicators. The Cochrane protocol for ensuring reliability was followed. The three researchers were then unblinded and met to resolve any disagreements in scoring to reach a consensus agreement. In each case of discrepancy, consensus was reached between the researchers. We developed criteria to standardise the process of quantifying each indicator. We also weighted and collated relevant national data from various sources to generate composite scores concordant with the key governance areas. We transformed these data to a scale of 0 (worst) to 100 (best), ranked countries on the basis of their mean scores, and used descriptive statistics to analyse global and regional trends.

Findings

306 NAPs were identified and 114 were eligible for analysis. Between 2020 and 2021, the mean antimicrobial resistance governance score was 51 (SD 14). Norway had the highest governance score (mean 85 [SD 32]), and the Federated States of Micronesia had the lowest governance score (28 [37]). The highest scoring domain was participation (83 [16]), and the lowest scoring domains were accountability (30 [18]) and feedback mechanism (30 [25]). Domains relating to policy design (55 [13]) and implementation tools (54 [17]) scored similarly, whereas monitoring and evaluation (38 [20]) efforts were lower.

Interpretation

International efforts to control antimicrobial resistance varied considerably between countries. Monitoring and evaluation efforts need improving for continuous understanding of national and international progress. International response might not be commensurate with the scale and severity of antimicrobial resistance.

Funding

None.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2023  The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 23 - N° 6

P. 706-718 - giugno 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study
  • Neil R Aggarwal, Kyle C Molina, Laurel E Beaty, Tellen D Bennett, Nichole E Carlson, David A Mayer, Jennifer L Peers, Seth Russell, Matthew K Wynia, Adit A Ginde
| Articolo seguente Articolo seguente
  • Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis
  • Roel P J Willems, Karin van Dijk, Maria J G T Vehreschild, Lena M Biehl, Johannes C F Ket, Sharon Remmelzwaal, Christina M J E Vandenbroucke-Grauls

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.